• Oramed filed a late notice for its quarterly report for period ended March 31, 2026, citing need for more time to complete and finalize financial statements.
• Form 10-Q expected to be filed on or before fifth calendar day after prescribed due date.
• Late notice indicated no anticipated significant change in results of operations versus corresponding prior-year period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057722), on May 15, 2026, and is solely responsible for the information contained therein.